Brain-Computer Interfaces

Brain-computer interfaces (BCIs) are revolutionizing paralysis treatment: Neuralink's first three human implants and Synchron's competing Stentrode have already restored thought-driven device control for 12 patients in 2026. These systems outperform #5 CRISPR therapies in their immediate real-world impact, enabling tetraplegic users to text at 8 words per minute with 94% accuracy. The interface achieves 10x faster signal processing than the average 2025 prototype, thanks to flexible polymer electrodes that capture neural activity from 1,024 channels simultaneously. With FDA approval now covering at-home use for 200 enrolled participants, BCIs have transitioned from experimental to prescribed therapy—a milestone that beats the typical six-year medical device cycle by three years.